A team of researchers from Kaunas University of Technology and Lithuanian University of Health Sciences proposed a non-invasive method for detection of melanoma. A patented computer-aided diagnostic system developed by Lithuanian scientists proved to be more than 90% accurate in detecting malignancy in diagnostic images of skin lesions acquired from 100 patients.
In Europe, melanoma is the fifth most common type of cancer and is the major cause of death from skin cancer. Northern Europe displays the largest age-standardised rate mortality of 3.8 per 10,000 in the region, with an incidence of 23.4.
Excision of a primary tumour remains essential in diagnosing melanoma, and the decision for the operation is generally based on the dermatoscopic evaluation of the lesion. However, the accuracy of melanoma clinical diagnosis is only at 65% and strongly relies on the experience of the physician-dermatologist carrying out the analysis.
“The novelty of our method is that it combines diagnostic information obtained from different non-invasive imaging technologies such as optical spectrophotometry and ultrasound. Based on the results of our research, we can confirm that the developed automated system can complement the non-invasive diagnostic methods currently applied in the medical practice by efficiently differentiating melanoma from a melanocytic mole”, says Professor Renaldas Raišutis, head of the team behind the research at Kaunas University of Technology.
In the study, carried out by the researchers of two Lithuanian universities, diagnostic images of skin lesions acquired from 100 different patients were evaluated. By comparing and analysing complex data on skin tumours recorded by different techniques, the researchers were able to develop a novel diagnostic system, differentiating melanoma from a benign nevus with accuracy higher than 90%.
“An efficient diagnosis of an early-stage malignant skin tumour could save critical time: more patients could be examined and more of them could be saved”, says Prof Raišutis.
According to Prof Raišutis, the novel diagnostic system is firstly aimed at medical professionals; he estimates that the price of the final product might be affordable even for smaller medical institutions. However, the team is also thinking about the solutions for individual use at home.
Following the research, the prototype of the technology was developed, and the clinical research is being carried out complying with the requirements of the protocol for the clinical research confirmed by the regional bioethics committee.
The invention was patented in Lithuania (Patent No. LT6670B) and the patent applications filed for Patent Cooperation Treaty and the United States Patent and Trademark Office.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Nutley Police Don Pink Badges For Breast Cancer Awareness
Have you seen a Nutley police officer wearing a pink badge or ribbon? There's a reason why, officials say. The Nutley Police Department released the following statement on Friday: "The Nutley Police ...
- OncoNano Announces $18.4 Million Equity Investment by the Cancer Prevention and Research Institute of Texas
OncoNano Medicine, Inc. today announced that the CPRIT will convert $18.4 million in grant award funding into an equity investment in OncoNano.
- As I’m A Celeb’s Adele Roberts is diagnosed with bowel cancer at 42 – the 10 signs to never ignore
BOWEL cancer can strike at any age, but knowing the signs can help catch it early. I’m A Celeb’s Adele Roberts revealed this weekend she had the disease to spread awareness of what to ...
- County recognizes Breast Cancer Awareness Month
Edie Ignacio Neumiller, Kaua‘i commissioner on the Hawai‘i State Commission on the Status of Women, said the wearing of pink by county Department of Water employees is a commission event that started ...
- Early detection, treatment key to containing cancer: DIG
Cancer is seen more in 40-50 years age-group, although it is likely to affect those in their 30s; most cases are reported in urban areas ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- US FDA grants fast track status to Ultimovacs’ universal cancer vaccine, UV1 to treat advanced malignant melanoma
US FDA grants fast track status to Ultimovacs’ universal cancer vaccine, UV1 to treat advanced malignant melanoma: Oslo, Norway Monday, October 25, 2021, 15:00 Hrs [IST] Ultimov ...
- Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma
A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced ...
- Paramedic cycles 1,000km around Riverina to raise awareness about melanoma
David Daly says he's seen a number of young families ripped apart by melanoma, so he's doing his best to raise awareness.
- Mother, 25, who used sunbeds twice a week for up to 14 minutes a session to 'banish winter depression' discovers 'tiny freckle' on her shin is Stage 2 melanoma
Paris Tippett, 25, from Crowthorne, Berkshire, went on sunbeds on and off from the age of 18, but started going twice-weekly for up to 14 minutes a session last year.
- Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma
UV1 as add-on therapy to checkpoint inhibitors awarded Fast Track designationProvides for potentially expedited review of UV1Ultimovacs to host webcast at 13.00 CET Thursday, 21 October 2021 OSLO, ...